Answers are grounded in this paper and cite their sources.
Historical review reveals mismatched glycopeptide resistance rates across international populations, indicating agricultural avoparcin use does not fully explain enterococcal resistance.
The reasons for the emergence and spread of vancomycin-resistant enterococci are not yet fully understood. Nevertheless, various hypotheses and proposals which are being vigorously and extensively debated have been advanced (1-7, 10, 11, 15, 17, 19). The use of avoparcin, another member of the glycopeptide class of antibiotics, as a growth-promoting agent in the production of food animals is often cited as playing a role in the spread of glycopeptide-resistant microorganisms (1, 18, 20). Although it is well recognized that vancomycin resistance is more prevalent in the United States than in Europe, it has not been explained why avoparcin usage fails to correlate with the different epidemiologies of resistance between the two continents; avoparcin was never approved for use in animals in the United States, in contrast to its broad use as a growth-promoting agent in Europe (5, 7, 10).
No takes yet. Share an insight, caveat, or question.
Kirst et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: